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B7-H1 (PD-L1) on immune cells plays an important
role in T cell coinhibition by binding its receptor
PD-1. Here, we show that both human and mouse
intestinal epithelium express B7-H1 and that B7-
H1-deficient mice are highly susceptible to dextran
sodium sulfate (DSS)- or trinitrobenzenesulfonic
acid (TNBS)-induced gut injury. B7-H1 deficiency
during intestinal inflammation leads to high mortal-
ity and morbidity, which are associated with severe
pathological manifestations in the colon, including
loss of epithelial integrity and overgrowth of
commensal bacteria. Results from bone marrow
chimeric and knockout mice show that B7-H1 ex-
pressed on intestinal parenchyma, but not on he-
matopoietic cells, controls intestinal inflammation in
an adaptive immunity-independent fashion. Finally,
we demonstrate that B7-H1 dampened intestinal
inflammation by inhibiting tumor necrosis factor a
(TNF-a) production and by stimulating interleukin 22
secretion from CD11c+CD11b+ lamina propria cells.
Thus, our data uncover a mechanism through which
intestinal tissue-expressed B7-H1 functions as an
essential ligand for innate immune cells to prevent
gut inflammation.
INTRODUCTION
The gut lumen hosts 90% of the microorganisms in the human
body. This microbiota community benefits the host by extracting
energy and nutrients from food, by preventing colonization of
pathogenic species (Hooper and Gordon, 2001), and by regu-
lating immune cell function (Maloy and Powrie, 2011). The
epithelial intestinal barrier is an essential boundary that pre-
cludes bacterial entry and maintains mucosal homeostasis.
Deregulation of intestinal homeostasis, with concomitant aber-Crant activation of mucosal innate and adaptive immunity, can
result in gut injury, inflammation, and inflammatory bowel dis-
ease (IBD). However, the fundamental pathophysiologic mecha-
nisms underlying IBD are still unclear.
The interaction between the B7 family members and their re-
ceptors provides critical costimulation and coinhibition, which
regulate T cell function. In addition to the long-established
pathway of B7-1/B7-2-CD28/CTLA-4, the interaction between
B7-H1 (PD-L1) (Dong et al., 1999; Freeman et al., 2000), a
member of the B7 family, and its receptor PD-1, a member of
the CD28 family, has a major role in inhibiting T cell responses
(Freeman et al., 2000) and in inducing CD8 T cell exhaustion
during viral infections (Day et al., 2006). Given that B7-H1 is
mainly expressed on immune cells and PD-1 is expressed
on activated T cells, research on this pathway has primarily
focused on T cell coinhibition; nonetheless, the role of the
B7-H1/PD-1 pathway in T cell-mediated intestinal inflammation
and IBD remains largely unknown. A few earlier works report
that the administration of anti-B7-H1 suppresses intestinal
inflammation (Kanai et al., 2003), whereas the loss of PD-1/
PD-L1 signaling leads to expansion of gut antigen-specific
CD8 T cells (Reynoso et al., 2009), and the PD-1 blockade
in simian-immunodeficiency-virus-infected monkeys enhances
repair of gut-associated junctions (Dyavar Shetty et al., 2012).
B7-H1 can also be detected on some tissue cells (Liang
et al., 2003), but its function is largely unexplored. Here, we
identified epithelium-expressed B7-H1 as a key regulator of
intestinal inflammation and colitis by inhibiting innate immune
cells.
RESULTS
B7-H1 Protects from Mortality and Morbidity in Two
Models of Intestinal Injury
To investigate B7-H1 function in gut immunity, we chose a
chemical model of intestinal injury utilizing oral administration
of dextran sodium sulfate (DSS) that injures the colonic epithe-
lium (Okayasu et al., 1990) and triggers potent inflammatory
responses (Rakoff-Nahoum et al., 2004). B7-H1-deficientell Reports 6, 625–632, February 27, 2014 ª2014 The Authors 625
Figure 1. B7-H1/ Mice Are Hypersensitive to DSS-Induced Intestinal Inflammation
(A) Wild-type (WT) and B7-H1/micewere fedwith 2%DSS in drinkingwater for 7 days. Survival, percentage of original weight loss, anal bleeding, diarrhea, anal
erosion, and colonic blood scores were monitored. Survival data are represented as Kaplan-Meier curves, ***p < 0.001; log rank test. Data were pooled from two
independent experiments (n = 15/group). *p < 0.05; **p < 0.01; ***p < 0.001; Student’s t test.
(B) H&E-stained colon tissue of DSS-treated WT and B7-H1/ mice (D0, D2, and D6).
(C and D) Histopathological scoring of infiltrating leukocytes, edema, ulcerationl, andMALT area (n = 20MALTs/mouse) inWT and B7-H1/mice (D6; scale bars
represent 100 mm; arrows indicate MALTs). ***p < 0.001; Student’s t test.
(E) DSS-fed mice were gavaged (D0 and D6) with FITC-dextran. Three hours later, FITC fluorescence was determined in sera. Data are pooled from two
independent experiments (n = 6–9). *p < 0.05; Student’s t test.
(F) CFUs in feces and colon of DSS-fed mice (D0, D2, and D6); *p < 0.05; Mann-Whitney U test.
(G) Quantitative PCR analysis of 16S rDNA copies for the whole bacterial kingdom in the feces of DSS-treated (D0 and D6) WT and B7-H1/ mice.
Data were pooled from two independent experiments, n = 3–4. *p < 0.05; Student’s t test.(B7-H1/) mice showed much higher mortality and morbidity
(weight loss, anal bleeding, diarrhea, and anal erosion scores)
upon DSS administration (2%; w/v) for 6 days (Figure 1A) than
wild-type (WT) mice. Although less than 20% of B7-H1/ mice
survived, more than 70% of WT mice remained alive. Higher
DSS concentration (4%) for a shorter time (5 days) provided
similar results with an earlier onset of disease (data not shown).
We extended studies to a 2,4,6-trinitrobenzenesulfonic acid
(TNBS)-induced colitis model and obtained similar results (Fig-
ure S1A). Thus, B7-H1 is critical for controlling intestinal epithelial
injury and inflammation.626 Cell Reports 6, 625–632, February 27, 2014 ª2014 The AuthorsWe dissected the causes of death and morbidity in B7-H1/
mice by histopathological analyses of colon tissues. Although
colonic bleeding in B7-H1/ mice occurred earlier than in WT
mice (Figure 1A), both groups of mice became anemic at day 6
of DSS treatment (data not shown). Hematoxylin and eosin
(H&E) analyses confirmed that B7-H1/ mice displayed more
severe ulceration, extensive epithelium erosion, and cellular infil-
tration (Figures 1B and 1C). In addition, we found an enlargement
of distinct lymphoid aggregations known as ‘‘mucosal associ-
ated lymphoid tissues’’ (MALTs) beneath the epithelium in B7-
H1/ mice (Figures 1B and 1D), which correlates with severe
pathological changes (Laukoetter et al., 2007). Neither naive
B7-H1/ nor naive WT mice showed signs of colonic inflamma-
tion or tissue damage.
Augmented mucosal permeability and intestinal barrier
dysfunction are associated with colitis development in mice
(Garrett et al., 2007) and IBD patients (Cobrin and Abreu,
2005). Therefore, we investigated the role of B7-H1 in maintain-
ing gut epithelial integrity by orally gavaging mice with fluores-
cein isothiocyanate (FITC)-dextran (Garrett et al., 2007). We
found a 4-fold increase of FITC-dextran levels in sera of B7-
H1/ mice at day 6 of DSS treatment (Figure 1E), suggesting
that B7-H1 is important for regulation of intestinal permeability
during gut injury.
Intestinal microbial populations vary enormously between IBD
patients and healthy individuals (Hooper and Gordon, 2001);
therefore, we analyzed their concentration and composition.
After DSS administration, B7-H1/ mice had higher bacteria
colony-forming units (CFUs) not only in feces and colon (Fig-
ure 1F), but also in mesenteric lymph nodes (MLNs), spleen,
and liver (data not shown) than WT mice, suggesting the pres-
ence of a bacterial systemic dissemination in B7-H1/ mice.
Quantitative analysis of 16S rDNA confirmed that B7-H1/
mice had an increased number of total bacteria than WT mice
(Figure 1G), but none of the specific intestinal microbiota groups
analyzed accounted for this increase (Figure S1B). Altogether,
our findings demonstrate that B7-H1 is required to maintain
gastrointestinal integrity during gut inflammation and to avoid
commensal bacteria overgrowth.
B7-H1 Expression on Intestinal Parenchyma Confers
Protection
B7-H1 is constitutively expressed on a wide range of immune
and tissue cells and is upregulated after activation (Freeman
et al., 2000; Liang et al., 2003). As the colon is the site of DSS-
induced disease, we examined B7-H1 expression in the colon.
Single-cell suspensions from colon of naive and DSS-treated
mice were analyzed by flow cytometry to detect hematopoietic
cells (cytokeratinCD45+) and parenchymal cells such as epithe-
lial cells (cytokeratin+CD45) or myofibroblasts and pericytes
(cytokeratinCD45) (Mifflin et al., 2011). We found B7-H1 was
expressed on both colonic parenchymal and hematopoietic cells
from naive and DSS-treated WT mice, and it was moderately
upregulated on cytokeratinCD45+ cells at D6 of DSS treatment
(Figure 2A). B7-H1 expression was also increased on colon of
IBD patients (Figure 2B).
PD-1, the receptor for B7-H1, is not expressed on paren-
chymal cells but is mainly expressed on activated T and B cells
(Agata et al., 1996), on exhausted CD8 T cells (Barber et al.,
2006; Day et al., 2006) and on dendritic cells (DCs) (Yao et al.,
2009) or monocytes or macrophages (Huang et al., 2009) during
infection. We detected PD-1 on colonic hematopoietic cells of
both WT and B7-H1/ mice before and after DSS administra-
tion, respectively (Figure 2A).
We next asked whether B7-H1 on hematopoietic cells and/or
parenchymal cells was required to inhibit the pathogenic pro-
cess during DSS-induced disease. We generated B7-H1 bone
marrow (BM) chimera mice with control groups (Figure S2A).
Upon DSS administration, B7-H1/ mice reconstituted withCWT BM developed significantly worse clinical symptoms as
compared to WT mice reconstituted with B7-H1/ BM or with
WT BM (Figure 2C). Only 10% of mice survived in the first group
versus 70%–80% in the other two groups. The first group also
showed severe histopathological changes in colon tissue sec-
tions stained with H&E (Figure 2D). These findings, together
with the B7-H1 expression pattern on colonic cell populations,
suggest that B7-H1 on parenchyma, but not on hematopoietic
cells, confers protection from intestinal injury and inflammation.
Effect of B7-H1 on Intestinal Epithelium Homeostasis
To understand how intestinal epithelium-expressed B7-H1 regu-
lates intestinal injury and inflammation, we considered two
possible mechanisms: cell-intrinsic alterations and cell-extrinsic
interactions. A possible cell-intrinsic mechanism could be a
homeostatic imbalance of intestinal epithelium in the absence
of B7-H1. We hypothesized that intestinal epithelium-expressed
B7-H1 controls intestinal injury by affecting proliferation or by im-
pairing apoptosis of intestinal epithelial cells. To assess the pro-
liferation, we used an immunofluorescence staining for Ki67 and
the 5-bromo-20-deoxyuridine (BrdU) assay. Our data showed a
slightly higher baseline level (D0) of proliferation in B7-H1/
mice (Figure S2B), which quickly disappeared at D2 and did
not correlate with an alteration of the intestinal epithelial perme-
ability (Figure 1E) or with colonic hyperplasia (data not shown).
However, upon inflammation (D6), both B7-H1/ and WT
colonic cells exhibited a similar epithelial proliferative capacity
(Figure S2B).
Another possible cell-intrinsic mechanism accounting for the
dysregulation of intestinal epithelial cells in B7-H1/ mice is
increased cell death. Analyses of apoptosis and necrosis in
colon epithelial cells showed an increased number of both
apoptotic and necrotic epithelial cells in B7-H1/ mice at D6
of DSS-treatment (Figures 3A and 3B). Altogether, these results
demonstrated that B7-H1 did not affect tissue repair processes
after an injurious insult, but it prevents apoptosis and necrosis of
intestinal epithelial cells during gut inflammation.
Protective Function of B7-H1 Is Not Dependent on
Adaptive Immunity
We next explored a cell-extrinsic mechanism by testing the
hypothesis that intestinal parenchymal cells expressed B7-H1
could interact with immune cells and, as a consequence, reduce
intestinal inflammation. Both innate and adaptive immunity
contribute to intestinal inflammation (Maloy and Powrie, 2011).
Therefore, we analyzed immune cell populations in the colon
and MLN and found no difference in the number of T and B cells,
NK/NKT cells, macrophages, DCs, neutrophils, myeloid, and
innate lymphoid cells (Figure S3A). To assess if components of
the adaptive immune system including T and B cells could
participate in the B7-H1-mediated protection, we generated
Rag-1/B7-H1/ mice and found that these mice exhibited
significant higher mortality and morbidity than Rag-1/mice af-
ter DSS administration (Figure 3C). Compared toWTmice recon-
stituted with WT BM, WT mice reconstituted with PD-1/ BM
seemed to be slightly more sensitive to DSS-induced colitis
without reaching significant difference (Figure 3D), which corre-
lates with no significant difference between PD-1/ mice andell Reports 6, 625–632, February 27, 2014 ª2014 The Authors 627
Figure 2. B7-H1 Is Expressed in Inflamed Colon and Is Required on the Parenchyma for Protection against DSS-Induced Colitis
(A) Fluorescence-activated cell sorting (FACS) plots of single-cell suspensions from colons of DSS-fed mice (D0 and D6) representing hematopoietic cells
(cytokeratinCD45+), epithelial cells (cytokeratin+CD45), and myofibroblast or pericytes (cytokeratinCD45) to detect B7-H1 and PD-1 expression (open
histograms), whereas shaded histograms indicate isotype control staining, n = 4.
(B) Immunohistochemistry staining for B7-H1 in human colon tissue from healthy donors and IBD patients and relative quantification. Isotype control was used.
Arrows and stars indicate focal expression of B7-H1; scale bars represent 200, 50, and 25 mm.Quantification is represented as amount of pixels positively stained
for B7-H1 by Velocity software. Data are representative of two independent experiments, n = 3. **p < 0.01; ***p < 0.001; Student’s t test.
(C) Three groups of bone-marrow chimera mice (B7-H1/ mice reconstituted with WT BM [WT BM/B7-H1/], WT mice reconstituted with B7-H1/ BM
[B7-H1/BM/WT], orWT BM [WT BM/WT]) were treated with 3%DSS in drinking water for 6 days. Survival, percentage of original weight loss, anal bleeding,
diarrhea, and anal erosion score were monitored. Data represent one of three independent experiments, n = 7–10. Survival data are represented as Kaplan-Meier
curve (*p < 0.05; log rank test). *p < 0.05; **p < 0.01; Student’s t test.
(D) H&E staining of colon tissue sections of chimera colons (D0 and D6). Scale bars represent 100 and 50 mm.WTmice during DSS treatment (Figure 3E). However, we cannot
exclude the involvement of PD-1 on radioresistant PD-1 positive
tissue resident innate cells.
These unexpected findings demonstrated that B7-H1 deliv-
ered protection from intestinal injury and inflammation in the
absence of adaptive immunity.
B7-H1 Inhibits Tumor Necrosis Factor a Production and
Enhances Interleukin 22 Production from
CD11c+CD11b+ LP Inflamed Cells
Tumor necrosis factor a (TNF-a) has been shown to have amajor
role in the pathogenesis of IBD (Dharmani et al., 2011). Thus, we
measured cytokines in the colon and found B7-H1/ colons628 Cell Reports 6, 625–632, February 27, 2014 ª2014 The Authorsproduced about 3-fold more TNF-a than WT colons at D6 of
DSS treatment (Figure 4A), whereas the levels of cytokines inter-
leukin 6 (IL-6), IL-2p70, IL-4, IFN-g, and MCP-1 were compara-
ble (Figure S3B).
Next, we evaluated innate immune cell activity in the colon.
Intracellular cytokine staining of inflamed LP cells (D6) revealed
that CD11c+CD11b+ cells in B7-H1/ mice significantly
enhanced TNF-a production (Figure S4A) despite a similar
expression of surface activation markers in both groups of
mice (data not shown). Treatment with anti-TNF-a neutralizing
antibody reduced by 50% the mortality in B7-H1/ mice as
compared to isotype-treated mice (Figure 4B). These data
indicate that TNF-a is one of the major causes of mortality in
Figure 3. B7-H1 Prevents Intestinal Cell Death, and Adaptive Immunity Is Not Needed for B7-H1 Function
(A) FACS plots for Annexin V+ epithelial cells and quantification of apoptotic epithelial cells in DSS-fed (D6) WT and B7-H1/ mice. *p < 0.05; Student’s t test.
(B) Dot plots and quantification of necrotic epithelial cells double positive for Annexin V and LIVE/DEAD Violet marker from DSS-fed (D6). Data represent one of
three independent experiments; n = 3/group. *p < 0.05; Student’s t test.
(C) B7-H1/Rag1/ and Rag1/ were treated with 3% DSS for 6 days and monitored for survival, body weight loss, anal bleeding, and diarrhea scores. Data
are pooled from two independent experiments, n = 17.
(D) WT mice were reconstituted with PD-1/ (PD-1/BM/WT) or WT bone marrow cells (WT BM/WT) and then treated with 3% DSS for 6 days. Survival,
percentage of weight loss, anal bleeding, and diarrhea scores were monitored. Data are representative of two independent experiments, n = 6–8.
(E) WT and PD-1/ mice were fed with 3% DSS in drinking water for 6 days and monitored for survival, body weight loss, anal bleeding, and diarrhea score.
Data are representative of four independent experiments, n = 9. Survival data are showed as Kaplan-Meier curves (*p < 0.05; log rank test). Data represent
means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; Student’s t test.B7-H1/ mice, suggesting a cell-extrinsic mechanism where
B7-H1 might inhibit TNF-a production from CD11c+CD11b+ LP
cells. To test this possibility, we generated a B7-H1-Ig fusion
protein and found that plate-bound B7-H1-Ig protein, but not
control Ig protein, suppressed TNF-a production from both WT
and PD-1/B7-1/ inflamed LP cells (Figure 4C) as B7-1 has
been found as an additional binding molecule (Butte et al.,
2007). These data indicate the PD-1/B7-H1 pathway alone or
the B7-1/B7-H1 pathway alone may not significantly contribute
to the disease onset in B7-H1/ mice.CIL-22 induces innate immune response during mucosal infec-
tions (Aujla et al., 2008) and promotes colonic epithelial cell
restitution including induction of antimicrobial peptides such
as Reg3-g (Zheng et al., 2008) and b-defensins (Wolk et al.,
2004). We investigated whether the cell-extrinsic mechanism
so far observed could promote a release of protective factors
like IL-22 and TGF-b. We found WT colon supernatants
had higher levels of IL-22 than B7-H1/ samples, but no dif-
ference for TGF-b was detected (Figure 4A). Interestingly, we
discovered IL-22 production was strongly produced by WTell Reports 6, 625–632, February 27, 2014 ª2014 The Authors 629
Figure 4. TNF-a Blockade Rescues B7-H1/ Mice from Intestinal Inflammation, and B7-H1-Expressing IECs Promote IL-22 Production
(A) Production of TNF, IL-22, and TGF-b in supernatant of colons fromDSS-fed (D0, D2, andD6)mice. Data are pooled from three independent experiments (n = 4).
(B) WT and B7-H1/ mice were intraperitoneally injected with anti-TNF-a blocking antibody or isotype control or PBS starting at D0 of 3% DSS treatment and
every other day until D20. Survival, percentage of original weight loss, anal bleeding, diarrhea, and anal erosion were monitored. Data were pooled from two
independent experiments (n = 8/group). Survival data are represented as Kaplan-Meier curves. **p < 0.01; ***p < 0.001; log rank test; *p < 0.05; **p < 0.01;
Student’s t test.
(C) LP cells were isolated fromWTor PD-1/B7-1/mice on day 6 after DSS treatment and incubated with plate-bound B7-H1-Ig or control Ig proteins for 24 hr.
LP cells were stained for CD11c+CD11b+ cells to detect percentage of intracellular TNF-a production by flow cytometry. Data are pooled from at least two
independent experiments. Each symbol represents an individual mouse. Data represent means ± SEM. *p < 0.05; Student’s t test.
(D) FACS plots and numbers of CD11b+CD103+ and CD11b+CD103 LP cells producing IL-22 from WT and B7-H1/ mice at day 6 of DSS treatment. Data
represent one of two independent experiments, n = 3. Data represent means ± SEM. *p < 0.05; Student’s t test.
(E) FACS plots and quantification of intracellular IL-22 production from CD11c+CD11b+ inflamed LP cells. LP cells were isolated from WT mice (D6 of DSS
treatment) and cocultured with naive IECs of WT or B7-H1/mice for 24 hr. Numbers above bracketed lines indicate percentage of IL-22-producing cells. Data
are pooled from two independent experiments (n = 3). *p < 0.05; Student’s t test.CD11b+CD103+ dendritic cells, which have a tolerogenic
phenotype (Maloy and Powrie, 2011), but not from
CD11b+CD103 DCs (Figure 4D). Finally, we found, in a cocul-
ture assay, WT primary intestinal epithelial cells (IECs) were
able to stimulate IL-22 production from WT CD11c+CD11b+
LP cells significantly better than B7-H1/ IECs (Figure 4E).
These data proved B7-H1 is required on the intestinal epithe-
lium to dampen the inflammation by CD11c+CD11b+ LP cells
in this disease model. Our results provide a mechanism by
which B7-H1 expressed on parenchyma colon reduces inflam-630 Cell Reports 6, 625–632, February 27, 2014 ª2014 The Authorsmation through inhibition of TNF-a and by promoting IL-22 pro-
duction from CD11c+CD11b+ LP cells. Altogether, our results
demonstrate that tissue-expressed B7-H1 is an essential regu-
lator in the control of intestinal inflammation.
DISCUSSION
Beside the classical coinhibitory function of the B7-H1/PD-1
pathway in T cell activation and immune pathology (Keir et al.,
2008), very few data are available on the role of tissue-expressed
B7-H1. Here, we reported a role for B7-H1 in reducing tissue pa-
thology during gut injury as demonstrated by severe morbidity
and mortality in B7-H1/ mice upon DSS or TNBS treatment.
We revealed two unexpected functions for B7-H1. First, B7-
H1-mediated protection during intestinal inflammation minimally
required the expression of PD-1 on hematopoietic cells because
the morbidity and mortality observed in PD1/ chimera mice
were slightly increased but were not statistically different from
that of control chimera mice. Second, B7-H1 expressed on tis-
sue cells, but not on hematopoietic cells, was essential for
reducing gut pathogenesis because chimera mice lacking B7-
H1 expression on parenchyma exhibited an increased mortality
and morbidity during DSS-induced colitis, whereas chimera
mice lacking B7-H1 expression on hematopoietic cells showed
minimal signs of disease. These results, together with other re-
ports in type 1 diabetes (Keir et al., 2006) and LCMV infection
(Mueller et al., 2010), highlight an emerging role for tissue-
expressed B7-H1 in the control of peripheral immune responses.
In addition, we found that adaptive immune response was not
required for B7-H1 protection, because Rag-1/B7-H1/
mice developed more severe gut pathogenesis than control
Rag-1/ mice. These data suggest that B7-H1 controls intesti-
nal inflammation through innate immunity, which is in line with
previous reports on the role of innate immunity in DSS-induced
colitis (Garrett et al., 2007; Rakoff-Nahoum et al., 2004; Zaki
et al., 2010).
TNF-a has been recognized as a master cytokine in the onset
of DSS-induced colitis (Dharmani et al., 2011), and anti-TNF-a
therapy inhibits IEC apoptosis in patients with IBD (Marini
et al., 2003). The increased TNF-a production observed in in-
flamedB7-H1/ colons correspondedwith the peak ofmortality
and intestinal epithelial apoptosis, and the disease was success-
fully ameliorated by TNF-a blockade, indicating that B7-H1 is
one of the major inhibitors of the TNF-a production in this dis-
ease model. An in vitro evidence of the B7-H1 inhibitory effect
was provided using B7-H1-Ig fusion protein, which impaired
the TNF-a production of inflamed CD11c+CD11b+ LP cells
isolated from WT or PD-1/B7-1/ mice. These data showed
not only that B7-H1 inhibited innate cells, but also that the B7-
H1/PD-1 pathway alone or the B7-H1/B7-1 pathway alonemight
not be primarily involved. In addition to PD-1 and B7-1, new
studies also demonstrate unidentified receptor(s) for B7-H1 (Xu
et al., 2013). Given that the multiple interactions of those mole-
cules could raise some difficulties for the data interpretation of
these different pathways, further investigations on the specific
functions of those molecules are warranted to better understand
their specific roles in the maintenance of intestinal peripheral
tolerance.
Different subsets of intestinal dendritic cells are known to
play crucial roles in the maintenance of intestinal tolerance by
inducing tolerogenic T cell responses including increasing
TGF-b and retinoic acid levels (Maloy and Powrie, 2011). Our
data showed that, although TGF-b was not differentially regu-
lated, IL-22 levels were significantly increased in mice express-
ing B7-H1. We further proved that IL-22 production was strongly
impaired when B7-H1/ IECs were cultured with DSS-inflamed
LP. These data revealed a role for B7-H1 expressed on IECs by
regulating IL-22 production for the epithelial restoration process.CThus, a lack of B7-H1 could skew the mucosal intestinal
responses toward a proinflammatory phenotype leading to
increased inflammation and injury. Strategies that specifically
enhance the activation of B7-H1 in the parenchyma would be
beneficial for therapeutic control of IBD.
EXPERIMENTAL PROCEDURES
Mice
B7-H1/ and PD-1/ mice were previously described (Dong et al., 2004).
C57BL/6, Rag1/ on C57BL/6 background, and B7-1/ on C57BL/6 back-
ground mice were purchased from the Jackson Laboratory and bred at the
Albert Einstein Animal Facility. Rag1/B7-H1/ and PD-1/B7-1/ mice
were obtained by intercrossing Rag1/ with B7-H1/ and PD-1/ with
B7-1/ mice, respectively. Mice were housed in the same room in a specific
pathogen-free facility and used for studies at 7–9 weeks old under protocols
approved by the Institutional Animal Care and Use Committee.
Experimental Colitis Models
DSS-mediated colitis was induced by oral administration of 2%, 3%, and 4%
(w/v) of DSS (molecular weight 36,000–50,000, MP Biomedicals) in drinking
water for 7, 6, and 5 days, respectively, ad libitum; then, water was replaced
until day 20. TNBS-mediated colitis was induced by intrarectal instillation of
2,4,6-trinitrobenzenesulfonic acid (TNBS) at 15 mg/kg body weight diluted
in 50% ethanol at day 0. The intensity of colitis for both models was moni-
tored daily and clinical parameters were determined as follows: anal erosion
(score 0–3; 0 = normal; 1 = mild; 2 = moderate; 3 = severe), anal bleeding
(score 0–3: 0 = normal; 1 = mild; 2 = moderate; 3 = severe), diarrhea (score
0–3; 0 = normal; 1 = mild; 2 = moderate; 3 = severe), and percentage of
body weight loss.
Statistical Analysis
Data were expressed as mean ± SEM. Student’s t test or Mann-Whitney test
were performed, and p values < 0.05 using a 95% confidence interval were
considered significant. Survival graphs were represented as Kaplan-Meier
curves and analyzed with log rank test. The GraphPad Prism statistical soft-
ware program (GraphPad Software) was used for all analyses.
Other detailed experimental procedures can be found in the Supplemental
Experimental Procedures.
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